Discrete event simulation and treatment sequencing cost-effectiveness model in second-line highly active relapse remitting multiple sclerosis for a NICE multiple technology appraisal

Sadek, Ayman, Manzano, Catalina Lopez, Cooper, Chris, Tomlinson, Eve, Rice, Claire M., Tallantyre, Emma C. ORCID: https://orcid.org/0000-0002-3760-6634, Alvarez, Javier Sanchez, Rodgers, Jeff W. and Thom, Howard 2025. Discrete event simulation and treatment sequencing cost-effectiveness model in second-line highly active relapse remitting multiple sclerosis for a NICE multiple technology appraisal. Presented at: ISPOR Europe 2025, Glasgow, Scotland, 09-12 November 2025. Value in Health. , vol.28 (Supp 1) Elsevier, 10.1016/j.jval.2025.09.720

Full text not available from this repository.

Abstract

We undertook a Multiple Technology Assessment (MTA) for the UK National Institute for Health and Care Excellence (NICE) assessing the cost-effectiveness of natalizumab as second line treatment for Highly Active Relapsing Remitting Multiple Sclerosis (HARRMS) in comparison to cladribine, ofatumumab, ocrelizumab and ublituximab. We addressed the shortcomings of prior Excel-based cohort Markov models by incorporating more flexible natural history modelling with up-to-date data, treatment switching, and severity-dependent mortality data.

Item Type:	Conference or Workshop Item (Paper)
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Publisher:	Elsevier
ISSN:	1098-3015
Last Modified:	07 Jan 2026 11:31
URI:	https://orca.cardiff.ac.uk/id/eprint/183651

Actions (repository staff only)

Edit Item